Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 1, 2010, Pages 83-96

  Haber, M M ^a   Hunt, B ^b   Freston, J W ^c   Peura, D A ^d   Kovacs, T O ^e   Atkinson, S ^b   Hisada, M ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; RANITIDINE;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ENDOCRINE CELL; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; STOMACH ANTRUM; STOMACH BIOPSY; STOMACH MUCOSA; UNSPECIFIED SIDE EFFECT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; DOUBLE-BLIND METHOD; ESOPHAGITIS; FEMALE; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; RANITIDINE; TIME FACTORS;

EID: 77953212630     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04310.x     Document Type: Article

References (33)

1. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 2002 287 : 1972 1981.
2. Katz PO. Review article: putting immediate-release proton-pump inhibitors into clinical practice - improving nocturnal acid control and avoiding the possible complications of excessive acid exposure. Aliment Pharmacol Ther 2005 22 (Suppl. 3 31 8.
3. Howden CW, Ballard D, Robieson W. Evidence of therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment of erosive esophagitis. Clin Drug Invest 2002 22 : 99 100.
4. Richter JE, Kahrilas PJ, Sontag SJ, Kovacs TO, Huang B, Pencyla JL. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol 2001 96 : 3089 3098.
5. Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996 124 : 859 867.
6. Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Haber M. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group. Am J Gastroenterol 1996 91 : 1758 1765.
7. Freston JW, Jackson RL, Huang B, Ballard ED 2nd. Lansoprazole for maintenance of remission of erosive oesophagitis. Drugs 2002 62 : 1173 1184.
8. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988 95 : 903 912.
9. Labenz J, Armstrong D, Lauritsen K, et al. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive esophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005 22 : 803 811.
10. Tytgat GN. Long-term use of proton pump inhibitors in GERD - help or hindrance? Aliment Pharmacol Ther 2001 15 (Suppl. 2 6 9.
11. Baldi F, Morselli-Labate AM, Cappiello R, Ghersi S Italian Lansoprazole Study Group. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. Am J Gastroenterol 2002 97 : 1357 1364.
12. Carling L, Axelsson C, Forsell H, et al. Lansoprazole versus omeprazole in long term maintenance treatment of reflux esophagitis: a Scandinavian multicentre trial. Gut 1996 39 (Suppl. 3 182.
13. Geboes K, Dekker W, Mulder CJ, Nusteling K Dutch Study Group. Long-term lansoprazole treatment for gastro-esophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther 2001 15 : 1819 1826.
14. Hatlebakk JG, Berstad A. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux esophagitis. Aliment Pharmacol Ther 1997 11 : 365 372.
15. Poynard T, Staub JL, Lemerez M, et al. Efficacy and safety of lansoprazole 15mg OAD or 30mg OAD as one year maintenance treatment for erosive reflux esophagitis: a randomized trial. Gastro-enterology 1995 108 (Suppl. A195).
16. Kovacs TO, Freston JW, Haber MM, Hunt B, Atkinson S, Peura DA. Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis. Dig Dis Sci 2009 54 : 1693 1701.
17. Freston JW, Hisada M, Peura DA, et al. The clinical safety of long-term lansoprazole for the maintenance of healed erosive esophagitis. Aliment Pharmacol Ther 2009 29 : 1249 1260.
18. Price AB. The Sydney System: histological division. J Gastroenterol Hepatol 1991 6 : 209 222.
19. Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in men. Digestion 1988 41 : 185 200.
20. Brinn NT. Rapid metallic histological staining using the microwave oven. J Histotechnol 1983 6 : 125 129.
21. Hirschowitz BI, Haber MM. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Aliment Pharmacol Ther 2001 15 : 87 103.
22. Hirschowitz BI, Haber MM. Chromogranin A in patients with acid hypersecretion and/or hypergastrinemia. Aliment Pharmacol Ther 2006 26 : 869 878.
23. Freston JW, Rose PA, Heller CA, Haber M, Jennings D. Safety profile of lansoprazole: the US clinical trial experience. Drug Saf 1999 20 : 195 205.
24. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000 118 : 661 669.
25. Thjodleifsson B, Rindi G, Fiocca R, et al. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther 2003 17 : 343 351.
26. Caos A, Breiter J, Perdomo C, Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther 2005 22 : 193 202.
27. Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001 64 : 205 213.
28. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008 40 : 650 658.
29. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996 334 : 1018 1022.
30. Eriksson NK, Kärkkäinen PA, Färkkilä MA, Arkkila PE. Prevalence and distribution of gastric intestinal metaplasia and its subtypes. Dig Liver Dis 2008 40 : 355 360.
31. Peura DA, Haber MM, Hunt B, Atkinson S. Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients. J Clin Gastroenterol 2010 44 : 180 185.
32. Lahner E, Bordi C, Cattaruzza MS, et al. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther 2005 22 : 471 481.
33. Hudson JI, Perahia DG, Gilaberte I, Wang F, Watkin JG, Detke MJ. Duloxetine in the treatment of major depressive disorder: an open-label study. BMC Psychiatry 2007 7 : 43.